Source: Nasdaq

Recursion: Why Recursion Pharmaceuticals Stock Is Skyrocketing Today

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday. The big gain for the biotech stock came after the U.S. Food and Drug Administration (FDA) announced on Thursday that it plans to replace the use of animals in testin

Read full article »

Recursion's Competitors | Recursion's News | Recursion's Financials

Followers on Owler

Annual Revenue

$25-100M

Employees

500-1.0K

Co-Founder & CEO

Christopher C. Gibson

CEO Approval Rating

81/100

Recursion is a Utah-based biotechnology company that discovers and commercializes drugs for the treatment of genetic, inflammation and infectious diseases.